pubmed.ncbi.nlm.nih.gov

Real-world data using mHealth apps in rhinitis, rhinosinusitis and their multimorbidities - PubMed

© 2022 The Authors. Clinical and Translational Allergy published by John Wiley and Sons Ltd on behalf of European Academy of Allergy and Clinical Immunology.

Conflict of interest statement

Ignacio J. Ansotegui reports personal fees from Roxall, personal fees from UCB, personal fees from Faes Farma, personal fees from Sanofi, personal fees from Bial, personal fees from Abbott, personal fees from Bayer, personal fees from Organon, outside the submitted work. Sinthia Bosnic‐Anticevich reports grants from TEVA, personal fees from TEVA, personal fees from TEVA, personal fees from AstraZeneca, personal fees from AstraZeneca, personal fees from Boehringer Ingelheim, personal fees from Boehringer Ingelheim, personal fees from GSK, personal fees from Sanofi, personal fees from Mylan, outside the submitted work; Jean Bousquet reports personal fees from Chiesi, Cipla, Hikma, Menarini, Mundipharma, Mylan, Novartis, Purina, Sanofi‐Aventis, Takeda, Teva, Uriach, other from KYomed‐Innov, outside the submitted work. Victoria Cardona reports personal fees from ALK, personal fees from Allergopharma, personal fees from GSK, grants from Thermofisher, outside the submitted work. Lorenzo Cecchi reports personal fees from Thermofisher, personal fees from Sanofi, personal fees from Astra Zeneca, personal fees from Novartis, outside the submitted work. Alvaro A. Cruz reports personal fees from AstraZeneca, personal fees from Boehringer‐Ingelheim, personal fees from CHIESI, personal fees from GSK, personal fees from SANOFI, personal fees from Novartis, personal fees from EUROFARMA, personal fees from Abdi‐Ibrahim, outside the submitted work. Philippe Devillier reports personal fees and non‐financial support from ALK_Abello, personal fees and non‐financial support from Stallergenes Greer, personal fees and non‐financial support from Astra Zeneca, personal fees and non‐financial support from Chiesi, personal fees from GlaxoSmithKline, personal fees from Sanofi, personal fees and non‐financial support from Mylan/Meda Pharma, personal fees and non‐financial support from Boehringer Ingelheim, personal fees and non‐financial support from Novartis, personal fees and non‐financial support from Menarini, outside the submitted work. Stephen R. Durham reports personal fees from ALK, personal fees from Revelo, personal fees from Angany, personal fees from Stallergenes, personal fees from Abbott, outside the submitted work. Motohiro Ebisawa reports personal fees from Mylan, personal fees from ARS Pharmaceutical, personal fees from Novartis, outside the submitted work; João A. Fonseca reports he is a co‐founder of a company that develops mHealth technologies. Tari Haahtela reports other from GSK, Orion Pharma, and Sanofi, outside the submitted work. Juan Carlos Ivancevich reports personal fees from Laboratorios Casasco, personal fees from Faes Farma, personal fees from Abbott Ecuador, personal fees from Bago Bolivia, outside the submitted work. Joaquim Mullol reports personal fees from ALK‐Abello, personal fees from Allergopharma, personal fees from Stallergenes, personal fees from Anergis, personal fees from Allergy Therapeutics, personal fees from Leti, personal fees from HAL, during the conduct of the study; personal fees from GSK, personal fees from Novartis, personal fees from Teva, personal fees from Takeda, personal fees from Chiesi, outside the submitted work. Piotr Kuna reports personal fees from Adamed, personal fees from Berlin Chemie Menarini, personal fees from Boehringer Ingelheim, personal fees from AstraZeneca, personal fees from Glenmark, personal fees from Krka, personal fees from Novartis, personal fees from Polpharma, personal fees from GSK, personal fees from Sanofi, outside the submitted work. Violeta Kvedariene reports other from Norameda, other from BerlinCHemie Menarini, outside the submitted work. Désirée E. Larenas‐Linnemann reports personal fees from ALK, Allakos, Amstrong, Astrazeneca, Chiesi, DBV Technologies, Grunenthal, GSK, Mylan/Viatris, Menarini, MSD, Novartis, Pfizer, Sanofi, Siegfried, UCB, Alakos, Gossamer, Carnot, grants from Sanofi, Astrazeneca, Lilly, Pfizer, Novartis, Circassia, UCB, GSK, Purina institute., outside the submitted work. Brian Lipworth reports personal fees from Glenmark, grants and personal fees from Mylan, grants from Sanofi, from AstraZeneca, from null, from null, during the conduct of the study; and Son of BJL employee of AstraZeneca. Paolo Maria Matricardi reports personal fees from TPS Productions, outside the submitted work. Joaquim Mullol reports personal fees and other from SANOFI‐GENZYME & REGENERON, personal fees and other from NOVARTIS, personal fees and other from ALLAKOS, grants and personal fees from MYLAN Pharma, grants and personal fees from URIACH Group, personal fees from Mitsubishi‐Tanabe, personal fees from Menarini, personal fees from UCB, personal fees from AstraZeneca, personal fees from GSK, personal fees from MSD, outside the submitted work. Robert Naclerio reports other from Sanofi, Regeneron, Lyra, Celgene, GSK, and AstraZeneca., outside the submitted work; Dr. Naclerio reports other from Sanofi, Regeneron, Lyra, Celgene, GSK, and AstraZeneca., outside the submitted work. Yoshitaka Okamoto reports personal fees from Torii Co.,Ltd., personal fees from ALK Co., Ltd., personal fees from Kirin Pharmaceutical Company, personal fees from Tanabe‐Mitsubishi Company, outside the submitted work.Nikolaos G. Papadopoulos reports other from Gerolymatos Int., other from Capricare, other from Nutricia, from ALK, Asit Biotech, AstraZeneca, Biomay, Boehringer Ingelheim, GSK, HAL, Faes Farma, Medscape, Menarini, MSD, Mylan/Meda, Novartis, Nutricia, OM Pharma, Regeneron, Sanofi, Takeda, outside the submitted work. Simone Pelosi reports personal fees from TPS Production, outside the submitted work; In addition, Dr. Pelosi has a patent PCT/IT2018/000119 pending. Oliver Pfaar reports grants and personal fees from ALK‐Abelló, grants and personal fees from Allergopharma, grants and personal fees from Stallergenes Greer, grants and personal fees from HAL Allergy Holding B.V./HAL Allergie GmbH, grants and personal fees from Bencard Allergie GmbH/Allergy Therapeutics, grants and personal fees from Lofarma, grants from Biomay, grants from Circassia, grants and personal fees from ASIT Biotech Tools S.A., grants and personal fees from Laboratorios LETI/LETI Pharma, personal fees from MEDA; Pharma/MYLAN, grants and personal fees from Anergis S.A., personal fees from Mobile Chamber Experts (a GA2LEN Partner), personal fees from Indoor Biotechnologies, grants and personal fees from GlaxoSmithKline, personal fees from Astellas Pharma Global, personal fees from EUFOREA, personal fees from ROXALL Medizin, personal fees from Novartis, personal fees from Sanofi‐Aventis and Sanofi‐Genzyme, personal fees from Med Update Europe GmbH, personal fees from streamedup! GmbH, grants from Pohl‐Boskamp, grants from Inmunotek S.L., personal fees from John Wiley and Sons, AS, personal fees from Paul‐Martini‐Stiftung (PMS), personal fees from Regeneron Pharmaceuticals Inc., personal fees from RG Aerztefortbildung, personal fees from Institut für Disease Management, personal fees from Springer GmbH, grants and personal fees from AstraZeneca, personal fees from IQVIA Commercial, personal fees from Ingress Health, personal fees from Wort&Bild Verlag, personal fees from Verlag ME, outside the submitted work; and member of EAACI Excom, member of ext. board of directors DGAKI; coordinator, main‐ or co‐author of different position papers and guidelines in rhinology, allergology and allergen‐immunotherapy. Sanna Toppila‐Salmi reports grants from GSK, personal fees from AstraZeneca, personal fees from ALK Abelló, personal fees from ERT, personal fees from GSK, personal fees from Novartis, personal fees from Sanofi Pharma, personal fees from Roche, outside the submitted work. Boleslaw Samolinski reports personal fees from Polpharma, personal fees from Viatris, grants and personal fees from AstraZeneca, personal fees from TEVA, personal fees from patient ombudsman, personal fees from Polish Allergology Society, grants from GSK, outside the submitted work; Joaquin Sastre reports grants and personal fees from SANOFI, personal fees from GSK, personal fees from NOVARTIS, personal fees from ASTRA ZENECA, personal fees from MUNDIPHARMA, personal fees from FAES FARMA, outside the submitted work. Ana Todo‐Bom reports personal fees from Astrazeneca, personal fees from GSK, personal fees from Novartis, personal fees from Bial, grants and personal fees from Leti, personal fees from Mylan, personal fees from AbbVie, grants and personal fees from Sanofi, outside the submitted work. Salvatore Tripodi reports personal fees from TPS Production, outside the submitted work; In addition, Dr. Tripodi has a patent PCT/IT2018/000119 pending. Ioanna Tsiligianni reports grants from Grants from Boehrniger Ingelheim, Glaxo Smithkline, Astra Zeneca and personal fees for advisory boards or speaker bureau from Astra Zeneca, Chiesi, Novartis, outside the submitted work. Charlotte Suppli Ulrik reports grants and personal fees from AZ, personal fees from GSK, grants and personal fees from BI, grants and personal fees from Sanofi, personal fees from Orion Pharma, personal fees from Pfizer, personal fees from TEVA, grants and personal fees from Novartis, outside the submitted work; Torsten Zuberbier reports personal fees from AstraZeneca, personal fees from AbbVie, personal fees from ALK, personal fees from Almirall, personal fees from Astellas, personal fees from Bayer Health Care, personal fees from Bencard, personal fees from Berlin Chemie, personal fees from FAES, personal fees from HAL, personal fees from Leti, personal fees from Meda, personal fees from Menarini, personal fees from Merck, personal fees from MSD, grants and personal fees from Novartis, personal fees from Pfizer, personal fees from Sanofi, personal fees from Stallergenes, personal fees from Takeda, personal fees from Teva, personal fees from UCB, grants from Henkel, personal fees from Kryolan, personal fees from L'Oréal, outside the submitted work; and Organisational affiliations; Commitee member: WHO‐Initiative ‘Allergic Rhinitis and Its Impact on Asthma’ (ARIA); Member of the Board: German Society for Allergy and Clinical Immunology (DGAKI); Board Chairman: European Centre for Allergy Research Foundation (ECARF); President: Global Allergy and Asthma European Network (GA2LEN); Member: Committee on Allergy Diagnosis and Molecular Allergology, World Allergy Organization (WAO).